In June 2012, we published a perspective on the challenges of drug–device combination products — a field that was then considered promising but operationally complex. Thirteen years later, the landscape has changed so fundamentally that the original question — whether the benefits justify the challenges — deserves a thorough revisit.
Where We Started
In 2012, our assessment was cautiously optimistic. The core argument was straightforward: merging pharmaceutical and medical device disciplines offered real clinical and commercial advantages, but the regulatory, engineering, and quality challenges were substantial — particularly around the question of whether drug and device manufacturing could realistically operate within a shared facility.
Our conclusion then was that "when weighing risks and challenges against benefits, the homeostasis shifts towards the merger." The manufacturing model we favored was two distinct facilities — separate but coordinated — as the most viable approach for managing divergent regulatory and engineering requirements.
That conclusion still holds. But almost everything around it has changed.
The products themselves are more sophisticated. The regulatory frameworks governing them are more demanding, more harmonized, and more globally interconnected. The manufacturing and quality expectations have risen substantially. And an entirely new dimension — digital health and connected devices — has introduced a category of complexity that did not meaningfully exist in 2012.
What follows is an honest reassessment of where the field stands today, what has evolved, and what it means for organizations navigating this space.
The Products Have Changed
In 2012, the primary examples of drug–device combination products were relatively straightforward: drug-eluting stents, prefilled syringes, inhalers, nebulizers, some orthopedic implants. The integration of drug and device was largely mechanical — a physical delivery system for a pharmaceutical agent.
Today, the category has expanded into territory that was largely conceptual in 2012. Wearable injectors that deliver large-volume biologics subcutaneously over hours. Smart inhalers that track adherence in real time and transmit data to healthcare providers. Autoinjectors with electronic feedback mechanisms. Implantable devices with drug-eluting components designed for controlled, sustained release over months or years.
The clinical ambition of combination products has grown alongside their technical sophistication. These are no longer primarily cost-reduction or convenience plays — they are integral to the therapeutic strategy in oncology, autoimmune disease, diabetes, rare disorders, and chronic pain management. The device is not incidental to the drug; in many cases, it is inseparable from the drug's clinical effectiveness.
This expansion of scope has amplified every challenge we identified in 2012 — and created several new ones.
Regulatory Complexity: More Demanding, More Harmonized, More Consequential
In 2012, the regulatory landscape for combination products was fragmented and, in many jurisdictions, still developing. The US FDA had frameworks in place, but global harmonization was limited. In India, combination product regulation was nascent.
The past decade has brought significant change on both fronts.
Primary Mode of Action (PMOA) determination has become a foundational regulatory question — and a contentious one. Whether a combination product is primarily regulated as a drug or as a device determines the regulatory pathway, the applicable quality standards, and the agency or directorate that leads the review. For products where the drug and device components interact dynamically, this determination is rarely straightforward. Getting it wrong has compounding consequences throughout the product lifecycle.
Human factors engineering (HFE) and usability studies are now mandatory requirements, not optional considerations. Regulators — including the US FDA and EMA — expect sponsors to demonstrate not just that a combination product is safe and efficacious, but that it can be used correctly by its intended users under realistic conditions. This means structured formative and summative usability studies, root cause analysis of use errors, and design iteration based on user feedback. For self-administration devices like autoinjectors and prefilled pens — where the consequence of a use error may be a missed dose of a biologic or an accidental needle stick — this is a genuinely demanding evidentiary standard.
Cybersecurity has emerged as an entirely new regulatory dimension. For digitally integrated combination products — connected inhalers, wearable drug delivery systems, implantable devices with software components — regulators now expect cybersecurity risk assessments, secure design practices, and post-market surveillance for software vulnerabilities. The US FDA's guidance on cybersecurity in medical devices has evolved considerably, and the EU MDR has introduced requirements that push in the same direction. In 2012, this was not a consideration. Today, it is a regulatory necessity for a growing proportion of combination products.
Post-market surveillance expectations have intensified. Both the EU MDR and the FDA's evolving frameworks require proactive, systematic post-market surveillance — not just passive adverse event reporting. Real-world evidence from clinical practice is increasingly expected to feed back into benefit-risk assessments over the product lifecycle. This places ongoing operational demands on manufacturers that extend well beyond the approval milestone.
In India, the regulatory framework for combination products has been slower to formalize, but the direction of travel is clear: increasing alignment with US FDA and EU MDR principles, greater scrutiny at the approval stage, and growing expectations around post-market data generation.
Quality Management: The Hybrid QMS Challenge
In 2012, we identified quality management as one of the areas of greatest stress in a combined drug–device organization. The challenge was structural: pharmaceutical quality systems (GMP) and medical device quality systems (ISO 13485, then the FDA's Quality System Regulation) were designed independently, for different product types, with different documentation philosophies and different approaches to validation and design control.
That structural challenge has not gone away. If anything, it has intensified.
The FDA's transition from the legacy Quality System Regulation (21 CFR Part 820) to alignment with ISO 13485 has moved the regulatory goalposts for device manufacturers — and created additional complexity for organizations that must simultaneously maintain GMP compliance for their pharmaceutical components. These two quality systems are not designed to be merged; they must be operated in parallel, with deliberate integration at the points where drug and device development and manufacturing intersect.
The practical implications are significant. Design controls — a device QMS requirement — must be applied to the device component of a combination product, including design history files, design verification and validation, and risk management under ISO 14971. Process validation — a GMP requirement — must be applied to the pharmaceutical component. Where the two components interact, both sets of requirements apply simultaneously. Managing this without gaps, overlaps, or contradictions requires quality professionals who are genuinely fluent in both domains — a capability that remains in short supply.
Modern practice has responded with digital QMS platforms that can manage documentation, change control, and compliance tracking across both frameworks from a single system. These platforms reduce the risk of version control errors and compliance gaps, but they do not eliminate the underlying complexity of operating under two regulatory paradigms simultaneously.
Engineering and Manufacturing: The Two-Facility Model Validated
Our 2012 recommendation — that operating drug and device manufacturing in two distinct facilities was the more viable model — has been validated by industry practice over the intervening decade. The "two-facility" or "segregated but integrated" model is now the accepted standard.
The reasons have not changed: sterilization requirements conflict (devices typically require terminal sterilization; pharmaceuticals may degrade under the same conditions), environmental controls differ (cleanroom classifications, HVAC requirements, contamination control protocols), and the regulatory audit burden of a fully integrated facility is operationally very difficult to manage.
What has changed is the scale and sophistication of outsourcing as a solution to these challenges. The growth of specialized CDMOs (Contract Development and Manufacturing Organizations) with combination product expertise has given sponsors an alternative to building integrated capabilities in-house. A CDMO with established GMP pharmaceutical manufacturing and ISO 13485 device assembly capabilities can manage the integration challenges on behalf of a sponsor — including the interface between the two facilities, the supply chain coordination, and the quality management alignment.
This model introduces its own complexities — multi-party quality agreements, supply chain risk management, technology transfer — but for many sponsors, particularly those developing combination products as part of a broader portfolio rather than as a core manufacturing competency, it is a more pragmatic path than building fully integrated in-house capabilities.
Material compatibility remains one of the most technically demanding aspects of combination product development. Drug–polymer interactions, leachables and extractables from device components, the stability of pharmaceutical agents in contact with device materials over extended periods — these require systematic study from early development, not as an afterthought. Regulatory submissions increasingly expect comprehensive extractables and leachables data, and gaps in this area have caused approval delays and post-market complications.
Clinical Development: No Longer the Easier Path
In 2012, we characterized clinical development as one of the segments "eased" by the drug–device merger — the argument being that clinical evaluation could leverage the established pharmaceutical trial infrastructure.
That characterization no longer holds. Clinical development for combination products has become one of the most demanding aspects of the regulatory pathway.
The core challenge is that a combination product must demonstrate the performance of both components — and their interaction — within a single clinical program. Efficacy and safety of the pharmaceutical agent must be established. The performance of the device component must be demonstrated under real-world conditions of use. And the interaction between the two — whether the device affects drug delivery, pharmacokinetics, or user behavior in ways that influence clinical outcomes — must be characterized.
Usability and human factors data, once collected outside the clinical trial, are now expected to be integrated into the clinical evidence package. For self-administration devices, this means studying not just whether the product works, but whether patients — with varying levels of health literacy, dexterity, and prior device experience — can use it correctly in their own homes.
Real-world evidence generation post-approval is increasingly a regulatory expectation, not just a commercial aspiration. For combination products with extrapolated indications, new patient populations, or novel delivery mechanisms, post-marketing studies that capture device performance and patient outcomes in routine clinical practice are becoming part of the approval conditions.
The Digital Dimension: What 2012 Could Not Anticipate
Perhaps the most significant development since 2012 is the emergence of digitally integrated combination products as a distinct and rapidly growing category.
Connected inhalers that measure dose delivery and adherence. Wearable patch injectors controlled via smartphone applications. Implantable drug delivery systems with remote monitoring capabilities. Combination products that generate continuous streams of patient data, transmit it wirelessly, and incorporate it into treatment algorithms — sometimes in real time.
These products introduce regulatory, engineering, and quality challenges that have no precedent in the traditional combination product framework. Software as a Medical Device (SaMD) requires regulatory classification and validation in its own right. Cybersecurity is a lifecycle concern, not a one-time approval requirement — software updates, patch management, and vulnerability monitoring must continue throughout the product's commercial life. Data privacy and interoperability with healthcare information systems introduce regulatory and legal dimensions that neither pharmaceutical nor medical device regulations were designed to address.
The regulatory frameworks are catching up, but the gap between product innovation and regulatory guidance remains significant. Organizations developing digitally integrated combination products are, in many cases, navigating terrain for which clear precedent does not yet exist — which demands both regulatory sophistication and a proactive engagement strategy with regulators.
The Strategic Case: Stronger Than Ever
Despite the intensification of every challenge we identified in 2012, the strategic case for combination products has not weakened. If anything, it has strengthened.
The commercial logic is compelling. In crowded therapeutic markets — where biologic drugs face biosimilar competition and differentiation is increasingly difficult to achieve on pharmacology alone — the delivery system has become a genuine source of competitive advantage. A drug that is easier to self-administer, more reliably delivered, better tolerated, and digitally connected to the prescriber's monitoring system is a meaningfully better product, not just a marginally more convenient one.
Regulatory exclusivity associated with combination product innovation provides periods of market protection that are difficult to replicate through formulation changes alone. And the patient adherence benefits of well-designed combination products translate into better outcomes data — which increasingly matters for payer access and reimbursement decisions.
The business case for combination products — product differentiation, lifecycle extension, market access, patient outcomes — is as strong today as it was in 2012. The complexity of execution has grown proportionately. The organizations that succeed are those that plan for that complexity from the earliest stages of development, engage the right expertise across regulatory, engineering, quality, and clinical domains, and treat the integration challenges as a core part of their development strategy rather than an operational afterthought.
Conclusion: The Same Verdict, A More Complex World
In 2012, we concluded that the balance of risks and benefits favored integration in drug–device combination products. Thirteen years later, that verdict stands — but with a clearer understanding of what it actually requires to execute successfully.
The regulatory burden is heavier. The quality management demands are more complex. The engineering challenges have multiplied with the emergence of digital health integration. The clinical evidence requirements have expanded. The post-market obligations are more substantial.
And yet the products are more clinically powerful, the commercial opportunity is larger, and the patient impact — in therapeutic areas where biologic delivery, adherence, and real-time monitoring can make a genuine difference to outcomes — is more significant than ever.
For sponsors navigating this space, the lesson of the past decade is clear: the complexity of combination product development is not a reason to avoid it. It is a reason to approach it with the right expertise, the right partners, and a regulatory and operational strategy that is integrated into the program from day one.
Genelife Clinical Research supports combination product development across regulatory strategy, clinical trial execution, quality management coordination, and post-marketing surveillance. To learn more, visit genelifecr.com.
This article is an update to our original 2012 perspective by our ex colluge Dr. Ashish Indani, Head of Clinical Operations, Genelife Clinical Research.(The Challenges with Drug/Device Combination Products; 2012)
Related Insights
Our expertise in Medical Devices
Innovations Shaping the Future of Clinical Trials: Genelife Perspective
CDSCO Approval Process for Clinical Trials in India: Complete Guide
No comments:
Post a Comment